OTCMKTS:XYNO Xynomic Pharmaceuticals (XYNO) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free XYNO Stock Alerts $2.22 0.00 (0.00%) (As of 06/23/2021) Add Compare Share Share Today's Range$2.22▼$2.2250-Day Range$2.22▼$2.2252-Week Range$0.20▼$3.84VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Xynomic Pharmaceuticals alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Xynomic PharmaceuticalsXynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.Read More XYNO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XYNO Stock News HeadlinesApril 25, 2024 | finance.yahoo.comNon-Hodgkin Lymphoma Pipeline Landscape 2024: Analysis of Over 220 Potential Pharmaceuticals in DevelopmentFebruary 21, 2024 | forbes.comWatson PharmaceuticalsApril 25, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…February 14, 2024 | wsj.comElite Pharmaceuticals Inc.January 8, 2024 | finance.yahoo.comHDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightNovember 1, 2023 | morningstar.comFennec Pharmaceuticals Inc FENCSeptember 1, 2023 | benzinga.comDelveInsight Highlights Major Advances, Transformative Therapies, and 195+ Leading Players Wheeling the Glioblastoma Clinical Trial Pipeline LandscapeMarch 13, 2023 | finance.yahoo.comDelveInsight Evaluates a Robust High-grade Glioma Pipeline as 120+ Influential Pharma Players to Set Foot in the DomainApril 25, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…October 7, 2022 | marketwatch.comPharmaceutical Secondary Packaging Equipment Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2028February 9, 2022 | finance.yahoo.comFollicular Lymphoma Market to Witness Expansion at a 6.85% CAGR during the Study Period [2018-2030], States DelveInsightJanuary 5, 2022 | investing.comXynomic Pharmaceuticals Holdings Inc (XYNO)August 7, 2021 | nz.finance.yahoo.comFollicular Lymphoma Drug Landscape Report 2021 - ResearchAndMarkets.comSee More Headlines Receive XYNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xynomic Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:XYNO CUSIPN/A CIKN/A Webxynomicpharma.com Phone86 21 5418 0212FaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Yinglin Xu (Age 50)Co-Founder, Pres, Chairman & CEO Ms. Jinwei Kou (Age 39)CFO & Chief Accounting Officer Comp: $62.69kDr. Wentao Wu Ph.D. (Age 54)Chief Operating Officer Comp: $160.01kDr. Sophia Paspal Ph.D. (Age 50)Chief Devel. Officer Comp: $252.55kMr. Tingzhi Qian (Age 42)Exec. Director Dr. James Jiayuan Tong M.D. (Age 48)Ph.D., Chief Strategy Officer, Exec. VP & Exec. Director More ExecutivesKey CompetitorsAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYAlseres PharmaceuticalsOTCMKTS:ALSEView All Competitors XYNO Stock Analysis - Frequently Asked Questions How have XYNO shares performed in 2024? Xynomic Pharmaceuticals' stock was trading at $2.22 on January 1st, 2024. Since then, XYNO stock has increased by 0.0% and is now trading at $2.22. View the best growth stocks for 2024 here. How do I buy shares of Xynomic Pharmaceuticals? Shares of XYNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:XYNO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWall Street Legend Issues New NVDA WarningChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xynomic Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
